Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLIT and NTRK-like family member 3 (SLITRK3)
- Target
- SLITRK3
- Molecular classification
- Synaptic cell adhesion molecule, Single-pass transmembrane protein, Receptor-associated protein (not a classical receptor, but a molecular organizer), Member of the Slitrk family (Slit and Trk-like proteins)
01
Overview
SLIT and NTRK-like family member 3 (SLITRK3) is a single-pass transmembrane synaptic cell adhesion molecule highly enriched at inhibitory synapses, where it promotes the differentiation and maintenance of inhibitory (GABAergic) synapses in the central nervous system. It interacts extracellularly with presynaptic receptor protein tyrosine phosphatase δ (PTPδ) and postsynaptically with neuroligin 2 (NL2), as well as intracellularly with gephyrin to stabilize synaptic architecture. Variants in SLITRK3 are implicated in neurodevelopmental disorders, especially those with epileptic features, and its expression is investigated as a prognostic marker in some cancers. SLITRK3 is not a classical neurotransmitter receptor or ion channel, but a molecular organizer guiding synapse formation and maturation.
- Other names
- SLITRK3SLIT and NTRK-like protein 3KIAA0848slit and trk like gene 3
02
Mechanism of action
Would most likely modulate inhibitory synapse formation, synaptic adhesion, and downstream GABAergic signaling
03
Biological functions
Inhibitory synapse development (especially GABAergic)Neurite outgrowth regulationStabilization of pre- and postsynaptic compartmentsCell adhesion at synaptic sitesInteractions with presynaptic receptor protein tyrosine phosphatase δ (PTPδ), postsynaptic neuroligin 2 (NL2), and intracellular gephyrin
04
Disease associations
Epileptic encephalopathies (implicated by mutations causing impaired synaptic development, seizures, intellectual disability, microcephaly, and global developmental delay)Neurological disorders (synaptopathies)Intellectual disabilityGastrointestinal stromal tumors (potential prognostic biomarker)
05
Safety considerations
Potential risk for developmental and neurological disorders if modulated inappropriately due to its critical function in inhibitory synapse developmentNo direct toxicity concerns described for agents targeting SLITRK3, as no drugs are in clinical use targeting it
06
Interacting drugs
None currently characterized or approved that directly target SLITRK3
07
Biomarkers
SLITRK3 expression itself may serve as a prognostic biomarker, especially in gastrointestinal stromal tumorsMutations/variants in SLITRK3 (e.g., C566R and E606X) for diagnosing or stratifying epileptic encephalopathies
Beyond the preview
Go deeper on SLIT and NTRK-like family member 3 (SLITRK3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLIT and NTRK-like family member 3 (SLITRK3).